ATE472334T1 - Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind - Google Patents

Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Info

Publication number
ATE472334T1
ATE472334T1 AT05716455T AT05716455T ATE472334T1 AT E472334 T1 ATE472334 T1 AT E472334T1 AT 05716455 T AT05716455 T AT 05716455T AT 05716455 T AT05716455 T AT 05716455T AT E472334 T1 ATE472334 T1 AT E472334T1
Authority
AT
Austria
Prior art keywords
modulating
polypeptide sequences
viral proteins
sequences involved
immunosuppressive effect
Prior art date
Application number
AT05716455T
Other languages
German (de)
English (en)
Inventor
Martial Renard
Marianne Mangeney
Thierry Heidmann
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE472334T1 publication Critical patent/ATE472334T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05716455T 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind ATE472334T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (1)

Publication Number Publication Date
ATE472334T1 true ATE472334T1 (de) 2010-07-15

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716455T ATE472334T1 (de) 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
EP2788372B1 (en) * 2011-12-07 2019-07-10 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
CA2912354C (en) 2013-06-07 2023-01-24 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
JP6864364B2 (ja) * 2015-06-11 2021-04-28 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、dna、及びベクター
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine
EP4392053A4 (en) * 2021-08-23 2025-06-25 Gabet, Yankel COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DISEASES OR CONDITIONS
WO2024218400A1 (en) 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
CN121717880A (zh) * 2025-12-25 2026-03-24 中国海洋大学青岛海上丝路研究院 许氏平鲉内源性逆转录病毒包膜蛋白percomORF、慢病毒载体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842B1 (en) 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
CA2429755A1 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US8178657B2 (en) 2012-05-15
JP5060284B2 (ja) 2012-10-31
JP2008506357A (ja) 2008-03-06
ES2347445T3 (es) 2010-10-29
ZA200608178B (en) 2008-10-29
EP1732585A1 (en) 2006-12-20
AU2005229411A1 (en) 2005-10-13
BRPI0509497B1 (pt) 2022-07-19
IL178205A (en) 2015-05-31
US20120189647A1 (en) 2012-07-26
US20080008683A1 (en) 2008-01-10
BRPI0509497A (pt) 2007-09-11
WO2005095442A8 (en) 2006-11-02
WO2005095442A1 (en) 2005-10-13
AU2005229411B2 (en) 2010-11-18
US8597657B2 (en) 2013-12-03
MXPA06011272A (es) 2007-04-17
DE602005022056D1 (de) 2010-08-12
CN1961001A (zh) 2007-05-09
CN1961001B (zh) 2012-09-05
CA2561376A1 (en) 2005-10-13
IL178205A0 (en) 2006-12-31
EP1732585B1 (en) 2010-06-30
CA2561376C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
PH12022552935A1 (en) Stabilized coronavirus spike protein fusion proteins
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
JOP20240256A1 (ar) بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج
MX2020006671A (es) Proteinas de fusion.
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
ATE542915T1 (de) Cst-ii-modifzierungen für erhöhte proteinexpression
ATE486128T1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
PH12022553417A1 (en) Stabilized corona virus spike protein fusion proteins
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker
WO2006047728A3 (en) Bmp gene and fusion protein
GB2469395A (en) Methods and compounds for phototransfer
WO2006058159A3 (en) Methods and compositions for the ex vivo high-throughput detection of protein/protein interactions
KR20040053279A (ko) 스트레스 저항성 및 내성 단백질을 코딩하는 유전자
AR068038A1 (es) Polipeptidos de la hormona de crecimiento modificada
DK1594991T3 (da) Fremgangsmåde til fremstilling af DNA-molekyler
ATE450546T1 (de) Impfstoffe mit ornithobakterium rhinotracheale- untereinheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties